Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
暂无分享,去创建一个
D. Schadendorf | K. Flaherty | P. Ascierto | R. Dummer | A. Ribas | G. Görgün | H. Tawbi | P. Nathan | G. Long | D. Gusenleitner | A. Savchenko | J. C. Brase | E. Gasal | C. Robert | J. Garrett